- Home
- OIA vs CCCC Comparison
OIA vs CCCC Comparison
Compare OIA & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OIA | CCCC |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.8M | 240.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | OIA | CCCC |
|---|---|---|
| Price | $5.97 | $2.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 97.9K | ★ 1.9M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 4.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,108,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.93 | $1.09 |
| 52 Week High | $6.72 | $4.26 |
Technical Indicators
Market Signals| Indicator | OIA | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 40.69 | 39.90 |
| Support Level | $6.00 | $1.93 |
| Resistance Level | $6.13 | $2.13 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 11.11 | 21.08 |
Price Performance
Historical ComparisonAbout OIA Invesco Municipal Income Opportunities Trust
Invesco Muni Income Opps Trust operates as a diversified closed-end management investment company. Its investment objective is to provide a high level of current income which is exempt from federal income tax.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.